Clinical Research Directory
Browse clinical research sites, groups, and studies.
Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
Sponsor: Hospital Regional de Alta Especialidad del Bajio
Summary
The choice of the best second-line therapy in patients with high LH R/R risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT. What is the progression-free survival and rate of metabolic responses complete in patients with high-risk R/R HL with the treatment strategy: BV+ PD-1 blockade consolidation with Auto-HSCT and maintenance with BV + PD-blockade 1?
Official title: Rescue With Brentuximab Plus PD-1 Blockade Followed by Autotransplantation and Consolidation With Brentuximab Plus PD-1 Blockade in Patients With Relapsed/Refractory Hodgkin Lymphoma: Exploratory Single-arm Analysis
Key Details
Gender
All
Age Range
15 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2022-10-18
Completion Date
2025-10-18
Last Updated
2025-03-12
Healthy Volunteers
Yes
Interventions
Brentuximab Vedotin 50 MG [Adcetris]
Brentuximab plus blocked PD-1 plus ASCT plus maintenance Brentuximab plus blocked PD-1
Locations (1)
Hospital Regional Alta Especialidad Bajio
León, Guanajuato, Mexico